Cybin (NASDAQ:HELP) CFO Buys $38,730.00 in Stock

Cybin Inc. (NASDAQ:HELP) CFO Greg Cavers purchased 3,000 shares of Cybin stock in a transaction dated Tuesday, September 29th. The stock was bought at an average price of $12.91 per share, with a total value of $38,730.00. Following the completion of the transaction, the chief financial officer owned 3,000 shares of the company’s stock, valued at $38,730. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Cybin Stock Performance

NASDAQ:HELP opened at $11.70 on Friday. The business’s fifty day moving average is $11.75 and its 200 day moving average is $7.56. The firm has a market cap of $921.73 million, a price-to-earnings ratio of -3.87 and a beta of 0.53. Cybin Inc. has a 52-week low of $3.76 and a 52-week high of $15.15.

Cybin (NASDAQ:HELP) last issued its earnings results on Friday, August 14th. The company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.11). Equities analysts predict that Cybin Inc. will post -2.95 EPS for the current fiscal year.

Institutional Trading of Cybin

A hedge fund recently bought a new position in Cybin stock. Pale Fire Capital SE acquired a new position in shares of Cybin Inc. (NASDAQ:HELP) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 153,505 shares of the company’s stock, valued at approximately $1,015,000. Pale Fire Capital SE owned approximately 0.21% of Cybin at the end of the most recent quarter. 17.94% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently commented on HELP. TD Cowen boosted their price objective on shares of Cybin from $8.00 to $62.00 and gave the company a “buy” rating in a research note on Thursday, August 20th. Barclays assumed coverage on shares of Cybin in a research note on Friday, September 18th. They issued an “overweight” rating and a $35.00 target price on the stock. Wells Fargo & Company assumed coverage on shares of Cybin in a report on Monday, July 27th. They issued an “overweight” rating and a $16.00 price target for the company. Finally, Wall Street Zen lowered shares of Cybin from a “sell” rating to a “strong sell” rating in a research report on Saturday. Six equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $46.33.

About Cybin

Cybin Inc is a clinical-stage biotechnology company focused on developing psychedelic-based therapeutics for mental health conditions. The company combines psychedelic compounds with drug-delivery technologies and treatment protocols designed to improve the safety, consistency and duration of psychedelic-assisted therapies.

Cybin’s development programs have included CYB003, an investigational deuterated psilocybin therapy being studied for major depressive disorder, and CYB004, an investigational formulation of N,N-dimethyltryptamine (DMT) being evaluated for generalized anxiety disorder.